AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37606856 — intervention group
Group type: COMPARATOR
Intervention: Neurotropic infections in the Dutch/Australian cohort (11 patients with neurological irAEs) compared to 27 control patients.
Number of subjects: 61
Study 37606856 — intervention group
Group type: COMPARATOR
Intervention: Neurotropic infections in the German cohort (13 patients with neurological irAEs) compared to 10 control patients.
Number of subjects: 61
Study 37606897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 0
Study 37606897 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37606907 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted techniques for graft hysterectomy after uterus transplantation
Number of subjects: 0
Study 37606923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention
Number of subjects: 1221
Study 37606923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 1221
Study 37606923 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1221
Study 37606965 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused-PPC model of care
Number of subjects: 192
Study 37606965 — intervention group
Group type: COMPARATOR
Intervention: Standard postnatal care
Number of subjects: 192
Study 37606979 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based PROM symptom monitoring program
Number of subjects: 39
Study 37606979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical alerts triggered by the PROM monitoring system
Number of subjects: 39
Study 37606979 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls in response to alerts
Number of subjects: 39
Study 37607074 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 855
Study 37607093 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct admission to specialized trauma center
Number of subjects: 970
Study 37607093 — intervention group
Group type: COMPARATOR
Intervention: Transfer from intermediate hospital
Number of subjects: 970
Study 37607096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T Cell Manufacturing using CliniMACS Prodigy
Number of subjects: 0
Study 37607203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) for 30 minutes each morning for 3-4 weeks
Number of subjects: 26
Study 37607311 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive workshops and written handouts
Number of subjects: 120
Study 37607311 — intervention group
Group type: COMPARATOR
Intervention: Written handouts only
Number of subjects: 120
Study 37607311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (workshop and written handouts)
Number of subjects: 120
Study 37607311 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone interviews of workshop group participants
Number of subjects: 120
Study 37607311 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops
Number of subjects: 120
Study 37607323 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported data via annual follow-up online questionnaires
Number of subjects: 11314
Study 37607323 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Warehouse Procedural Process (DWPP)
Number of subjects: 11314
Study 37607323 — intervention group
Group type: COMPARATOR
Intervention: Self-report only
Number of subjects: 11314
Study 37607323 — intervention group
Group type: COMPARATOR
Intervention: DWPP alone
Number of subjects: 11314
Study 37607323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined self-reported data with EHR data from a health system data warehouse registry
Number of subjects: 11314
Study 37607422 — intervention group
Group type: COMPARATOR
Intervention: Intensive Lifestyle (ILS)
Number of subjects: 0
Study 37607422 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 0
Study 37607422 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PLB)
Number of subjects: 0
Study 37607457 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 309
Study 37607457 — intervention group
Group type: COMPARATOR
Intervention: Non-HCT treatment
Number of subjects: 309
Study 37607644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene glycol-free melphalan (PGF-Mel) at 140 to 200 mg/m²
Number of subjects: 28
Study 37607644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene glycol-free melphalan (PGF-Mel)
Number of subjects: 28
Study 37607661 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI with hydrofluoroolefin-1234ze (HFO)
Number of subjects: 47
Study 37607661 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI with hydrofluorocarbon-152a (HFC)
Number of subjects: 47
Study 37607661 — intervention group
Group type: COMPARATOR
Intervention: BGF MDI with hydrofluoroalkane-134a (HFA)
Number of subjects: 47
Study 37607748 — intervention group
Group type: EXPERIMENTAL
Intervention: Full next-generation sequencing (NGS) genetic panel
Number of subjects: 335
Study 37607748 — intervention group
Group type: COMPARATOR
Intervention: Partial genetic panel offered by the Quebec Ministère de la Santé et des Services sociaux (MSSS)
Number of subjects: 335
Study 37607780 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab intensified regimen (IR) 900 mg for the first 3 doses followed by 300 mg every 4 weeks
Number of subjects: 147
Study 37607780 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab basic regimen (BR) 300 mg every 4 weeks
Number of subjects: 147
Study 37607780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 37607780 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab IR
Number of subjects: 147
Study 37607780 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab BR
Number of subjects: 147
Study 37607780 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab IR and BR
Number of subjects: 147
Study 37607787 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multicomponent exercise programme
Number of subjects: 320
Study 37607787 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple multicomponent exercise programme (walking and sit-to-stand exercises)
Number of subjects: 320
Study 37607787 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 37607809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering TNFi to discontinuation
Number of subjects: 84
Study 37607809 — intervention group
Group type: COMPARATOR
Intervention: Stable TNFi
Number of subjects: 84
Study 37608129 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma copper (Cu) levels
Number of subjects: 34
Study 37608248 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofibromatosis type 1 (NF1) group
Number of subjects: 16
Study 37608248 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofibromatosis type 1 (NF1) group during working memory task
Number of subjects: 16
Study 37608248 — intervention group
Group type: COMPARATOR
Intervention: Typically developing control group
Number of subjects: 16
Study 37608248 — intervention group
Group type: COMPARATOR
Intervention: Typically developing control group during working memory task
Number of subjects: 16
Study 37608269 — intervention group
Group type: COMPARATOR
Intervention: 20 ml group (ESB with 10 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 7 ml of saline 0.9%)
Number of subjects: 50
Study 37608269 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml group (ESB with 15 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 12 ml of saline 0.9%)
Number of subjects: 50
Study 37608287 — intervention group
Group type: EXPERIMENTAL
Intervention: Invimestrocel plus standard treatment
Number of subjects: 30
Study 37608287 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study 37608315 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine administered intravenously for five days at a dosage of 100 mg bid.
Number of subjects: 43
Study 37608315 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (if non-responders, dosage doubled from day three to five).
Number of subjects: 43
Study 37608315 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine treatment.
Number of subjects: 43
Study 37608321 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of cervical lordosis group
Number of subjects: 57
Study 37608321 — intervention group
Group type: COMPARATOR
Intervention: Normal cervical lordosis group
Number of subjects: 57
Study 37608354 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjusting compression garment (ReadyWrap®)
Number of subjects: 0
Study 37608354 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of compressive bandaging
Number of subjects: 0
Study 37608354 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of compressive mesh
Number of subjects: 0
Study 37608354 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of compressive bandaging and compressive mesh
Number of subjects: 0
Study 37608391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 710
Study 37608391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 37608391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 710
Study 37608389 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ intervention, practiced at home with a 45-min video, at least 3 times per week for 12 weeks.
Number of subjects: 69
Study 37608389 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ intervention
Number of subjects: 69
Study 37608390 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance through reduction (via relocation and reduction in personal smoking) and cessation intervention
Number of subjects: 500000
Study 37608390 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance through resident endorsement intervention
Number of subjects: 500000
Study 37608390 — intervention group
Group type: EXPERIMENTAL
Intervention: A plus B (both interventions)
Number of subjects: 500000
Study 37608390 — intervention group
Group type: COMPARATOR
Intervention: NYCHA standard approach
Number of subjects: 500000
Study 37608471 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg)
Number of subjects: 30
Study 37608473 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent health care intervention
Number of subjects: 225
Study 37608568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises (CSEs) in addition to conventional exercises (CEs)
Number of subjects: 25
Study 37608568 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises (CEs)
Number of subjects: 25
Study 37608590 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss condition
Number of subjects: 71
Study 37608590 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 71
Study 37608909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure biofeedback-guided DCFM strength training and conventional treatment
Number of subjects: 60
Study 37608909 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy and conventional treatment
Number of subjects: 60
Study 37609003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane emulsion (DDFPe) administered via intravenous infusion at doses of 0.05, 0.10, or 0.17 mL/kg while breathing supplemental oxygen prior to each 2 Gy fraction of radiotherapy (30 fractions over 6 weeks) along with standard-of-care chemotherapy (temozolomide).
Number of subjects: 11
Study 37609003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane emulsion (DDFPe) administered at 0.1 mL/kg dose level.
Number of subjects: 11
Study 37609269 — intervention group
Group type: COMPARATOR
Intervention: Step Activity Monitoring (SAM)
Number of subjects: 250
Study 37609269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (FAST+SAM)
Number of subjects: 250
Study 37609269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity walking intervention (FAST)
Number of subjects: 250
Study 37609318 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy
Number of subjects: 0
Study 37609318 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37609358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous treprostinil
Number of subjects: 0
Study 37609358 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous treprostinil
Number of subjects: 0
Study 37609358 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high-dose vs low-dose treprostinil
Number of subjects: 0
Study 37609651 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line anti-seizure medications (ASMs) as substitution therapy
Number of subjects: 102
Study 37609651 — intervention group
Group type: COMPARATOR
Intervention: Second-line anti-seizure medications (ASMs)
Number of subjects: 102
Study 37609698 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel only at the start of PCI
Number of subjects: 77
Study 37609698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor plus prasugrel concomitantly at the start of PCI
Number of subjects: 77
Study 37609698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor at the start of PCI plus prasugrel at the end of infusion
Number of subjects: 77
Study 37609714 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pertuzumab and trastuzumab fixed-dose combination administered subcutaneously plus taxane-based chemotherapy
Number of subjects: 0
Study 37609778 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery and endocrine therapy (no other systemic therapy)
Number of subjects: 0
Study 37609778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67 immunohistochemistry assessment
Number of subjects: 0
Study 37609778 — intervention group
Group type: EXPERIMENTAL
Intervention: IKWG-recommended scoring method
Number of subjects: 0
Study 37609806 — intervention group
Group type: EXPERIMENTAL
Intervention: Social determinants of health (SDoH)
Number of subjects: 0
Study 37609931 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 5661
Study 37609931 — intervention group
Group type: COMPARATOR
Intervention: ramipril
Number of subjects: 5661
Study 37609948 — intervention group
Group type: COMPARATOR
Intervention: Moderate chocolate consumption (Mod-Ch) >1-6 servings/week
Number of subjects: 3931
Study 37609948 — intervention group
Group type: EXPERIMENTAL
Intervention: No/Low chocolate consumption (No/Low-Ch) ≤1 servings/week
Number of subjects: 3931
Study 37609948 — intervention group
Group type: COMPARATOR
Intervention: High chocolate consumption (High-Ch) >6 servings/week
Number of subjects: 3931
Study 37609981 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque score
Number of subjects: 3650
Study 37609981 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque score cutoff >3
Number of subjects: 3650
Study 37610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led package of care (non-pharmacological treatment)
Number of subjects: 208
Study 37610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 208
Study 37610332 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208
Study 37610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 208
Study 37610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study feasibility
Number of subjects: 208
Study 37610383 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized attachments (O)
Number of subjects: 40
Study 37610383 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal attachments (H)
Number of subjects: 40
Study 37610383 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal incisally-beveled attachments (HIB)
Number of subjects: 40
Study 37610383 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal gingivally-beveled attachments (HGB)
Number of subjects: 40
Study 37610383 — intervention group
Group type: COMPARATOR
Intervention: Horizontal attachments (H, HIB, HGB combined)
Number of subjects: 40
Study 37610533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 50-1000 mg intravenously every 4 weeks as induction treatment
Number of subjects: 1362
Study 37610533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg subcutaneously every 4 or 12 weeks as maintenance treatment
Number of subjects: 1362
Study 37610533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab (general)
Number of subjects: 1362
Study 37610564 — intervention group
Group type: EXPERIMENTAL
Intervention: CD exclusion diet plus partial enteral nutrition for 12 weeks
Number of subjects: 21
Study 37610564 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 21
Study 37610727 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 178
Study 37610727 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 178
Study 37610731 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision Strategy (PS)
Number of subjects: 2103
Study 37610731 — intervention group
Group type: COMPARATOR
Intervention: Usual Testing (UT)
Number of subjects: 2103
Study 37610747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific psychotherapy (32 sessions)
Number of subjects: 254
Study 37610747 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-specific psychotherapy (32 sessions)
Number of subjects: 254
Study 37610757 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflation in the cardiac coronary sinus (CS)
Number of subjects: 20
Study 37610768 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred testing
Number of subjects: 422
Study 37610768 — intervention group
Group type: COMPARATOR
Intervention: Usual testing
Number of subjects: 422
Study 37610800 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased standing (STAND) via smartphone app prompts to stand for an additional 6 minutes each hour
Number of subjects: 15
Study 37610800 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased moving (MOVE) via smartphone app prompts to move for an additional 6 minutes each hour
Number of subjects: 15
Study 37610800 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased standing (STAND)
Number of subjects: 15
Study 37610800 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased moving (MOVE)
Number of subjects: 15
Study 37610800 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased standing (STAND) and Increased moving (MOVE)
Number of subjects: 15
Study 37610803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib (D+T)
Number of subjects: 110
Study 37610803 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus Vincristine (C+V)
Number of subjects: 110
Study 37610821 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (animated videos)
Number of subjects: 1056
Study 37610821 — intervention group
Group type: COMPARATOR
Intervention: Text-only intervention
Number of subjects: 1056
Study 37610821 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (36-75 years)
Number of subjects: 1056
Study 37610927 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal breastfeeding education
Number of subjects: 76
Study 37610927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postnatal breastfeeding education)
Number of subjects: 76
Study 37611007 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop ventilation using sidestream capnography
Number of subjects: 80
Study 37611007 — intervention group
Group type: COMPARATOR
Intervention: Closed-loop ventilation using mainstream capnography
Number of subjects: 80
Study 37611121 — intervention group
Group type: EXPERIMENTAL
Intervention: Divarasib (GDC-6036) administered orally once daily at doses ranging from 50 to 400 mg
Number of subjects: 137
Study 37611156 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan 80 mg/m2 as outpatients on days -20 and -13 before transplant, Fludarabine 40 mg/m2 on days -6 to -3, busulfan dosed to achieve a target AUC of 20,000 mol/min for the whole course.
Number of subjects: 78
Study 37611156 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan regimen
Number of subjects: 78
Study 37611174 — intervention group
Group type: EXPERIMENTAL
Intervention: ASICA app for monthly total-skin self-examinations (TSSE)
Number of subjects: 14
Study 37611174 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study of barriers and facilitators to TSSE adherence using the app
Number of subjects: 14
Study 37611246 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine 500 mg TID for 20 weeks
Number of subjects: 43
Study 37611246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 37611283 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline Catheter (MC) with differing antithrombotic properties
Number of subjects: 191
Study 37611354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-care intervention
Number of subjects: 139
Study 37611354 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy
Number of subjects: 139
Study 37611527 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and Progesterone (EP)
Number of subjects: 26
Study 37611527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 37611731 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero Gravity (ZG) system
Number of subjects: 71
Study 37611731 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation protection
Number of subjects: 71
Study 37611799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Chemoembolization
Number of subjects: 0
Study 37611857 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG (pullback pressure gradient) assessment pre-PCI
Number of subjects: 982
Study 37612008 — intervention group
Group type: EXPERIMENTAL
Intervention: HM3 LVAD
Number of subjects: 485